Eloxx Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule drugs that coax the body's protein-building machinery to "read through" genetic errors called nonsense mutations, which cause rare diseases like Alport syndrome. Its lead investigational drug, exaluren, aims to restore full-length functional proteins in patients with these conditions. Founded in 2013 by two scientists, the company went public in 2017 through a reverse merger with Sevion Therapeutics, and its name echoes the "ELX" prefix of its drug compounds.
Granted 1.28M
Granted 1.9K
Granted 1.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Aggarwal SumitPresident and CEO, Director, 10% owner · 3 transactions | +321.6% | 1.67M | 1.28M | — | — |
| Domicilium Real Estate Fund III LP10% owner · 3 transactions | — | 642.9K | — | — | — |
| Walts Alan EdmundDirector · 1 transaction | -6.7% | 15.6K | 1.9K | — | — |
| Rubin Steven DDirector · 1 transaction | -7.1% | 14.6K | 1.9K | — | — |
| Coastlands Capital LP10% owner · 1 transaction | — | 0 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.